New rapid cancer injection promises to change patients’ routine, but is not yet available in Northern Ireland

A researcher at Queen’s University Belfast warned of disparities in access to an innovative immunotherapy drug at Reino Unido. Professor Mark Lawler said Irlanda and Norte patients should not be left behind in a “postcode lottery” while other parts of the kingdom already implement the new injectable form of pembrolizumab, known commercially as Keytruda. The medication, already available to Serviço Nacional of Saúde (NHS) of Inglaterra and País of Gales patients since Monday, is still awaiting approval in Irlanda of Norte.

Departamento of Saúde of Irlanda of Norte reported being aware of the vaccine and analyzing how to make it available to patients as quickly as possible. Essa’s delay contrasts with the rapid implementation of Reino Unido in other regions and represents a major challenge to equitable access to innovative treatments in the UK healthcare system.

Revolucionário breakthrough in cancer treatment

Pembrolizumab is an immunotherapy medication that works by unlocking the immune system’s defense mechanisms. Cancer can hide from the body’s own protective system by producing specialized proteins that send a “stop signal” to immune cells, preventing them from attacking cancer cells. Cientistas describe this tumor strategy as a disease that hides behind a “cloak of invisibility.” Immunotherapy works precisely by blocking this stop signal, allowing the immune system to recognize and destroy malignant cells more efficiently.

Essa’s revolutionary approach yielded two scientists James Allison and Tasuku Honjo, the Prêmio Nobel of Medicina in 2018. Keytruda was one of the first immunotherapy drugs to receive international approval, initially for the treatment of skin cancer and later extended to other forms of the disease. Atualmente, according to most market indicators, is the best-selling prescription medicine in the world, with global sales of 30 billion dollars, equivalent to 22 billion pounds, in 2025.

Redução significant in hospitalization time

The injectable version of pembrolizumab promises to transform the experience of NHS patients. Desde 2015, British patients received the medicine via intravenous drip, a process that could take more than an hour to be completely administered in hospital units. The new injectable formulation drastically changes this scenario. The treatment will be administered as a one-minute injection every three weeks, or as a two-minute injection every six weeks, depending on each patient’s specific cancer diagnosis.

NHS England reckons this change will save valuable time for both patients and healthcare staff. Pacientes will no longer spend hours waiting for infusions in medical centers, also freeing up hospital capacity for other treatments. One of the most important advantages is that waiting times in hospitals will be reduced by half in many cases. Profissionais will have greater operational efficiency, increasing the number of patients treated without the need for immediate expansion of existing infrastructure.

Mark Lawler, a researcher with over 30 years of experience in oncology research, described the development for the BBC Good Morning Ulster program Radio Ulster:

• A very important development in modern oncology
• A truly innovative approach that represents the biggest advance in immunotherapy in the last 25 years
• Good news for patients, who will have less hospitalization time
• Good news for the healthcare system, which will be able to operate much faster
• A double win: better patient care and operational efficiency

Disparidade regional and zip code lottery

Lawler emphasized that the non-immediate availability of the medicine in Irlanda from Norte represents a serious issue of equity in access to healthcare. Ele specifically criticized the concept of the “postcode lottery”, referring to the situation where British patients receive different levels of care depending on where they live. “The first thing we need to do is secure this for Irlanda from Norte. Não we want another zip code lottery,” the researcher said.

Leia Também

Lake isolated 12 thousand years ago is home to millions of unique jellyfish on the planet

Two X-class solar flares hit Earth in seven hours and disrupt radio

Steam Controller arrives with innovative trackpads and user-serviceable design

The professor argued that patients should receive the same standard of care regardless of their geographic location at Reino Unido. Ele highlighted that regardless of whether a patient is in Belfast, Birmingham, Bradford or Burton-on-Trent, access to innovative medicines should be uniform. Conversas with colleagues at Escócia revealed similar frustration, as that country is also still unable to offer the medicine to its patients. Lawler expressed satisfaction with Departamento’s search for ways to bring the new formulation to Irish-Norman patients and offered to help in any way possible.

Questões financial and practical implementation

While Embora Lawler was unable to comment specifically on whether the department’s financial constraints were the reason for the delay in Irlanda’s Norte, its assessment suggests that budgetary factors likely contribute to the situation. Ele noted that it is important to recognize that sometimes healthcare institutions need to carefully analyze a situation and determine, “This will help save the healthcare system money while providing the best care possible for cancer patients.”

The researcher characterized this situation as a win-win scenario for all sides. Patients receive access to more efficient and less invasive treatment. The healthcare system saves time and operational resources. Ainda although there are administrative and financial obstacles, Lawler stressed that the time savings generated by the injection significantly reduce hospital capacity problems. Não is a logistical obstacle, according to his analysis, but apparently a financial issue that needs to be resolved by the competent health bodies.

Como the medicine arrived here

Medicines regulator Reino Unido’s approval of injectable pembrolizumab paved the way for NHS hospitals in all four British nations to order the new formulation. However, implementation is not centralized. Cabe to individual hospitals and local healthcare facilities to implement distribution according to their own operational schedules. Essa decentralization explains why some regions, such as Inglaterra and País from Gales, have achieved rapid implementation while others are still working on the necessary logistics.

A company representing the drug’s manufacturer clarified to BBC News NI that each local health institution has the autonomy to define when it will start prescribing. Isso means that infrastructure, staff training and administrative planning need to be in place before any patient receives the injection. Departamento of Saúde of Irlanda of Norte is analyzing the best way to comply with this operational transition for its population.

Impacto history of immunotherapy

The discovery of immunological mechanisms against cancer marked a turning point in contemporary oncological medicine. Durante decades, scientists tried to understand why the immune system could not fight cancer cells even if they were present in the body. The answer came with the discovery of immune “checkpoint” proteins, those stop signals that cancer uses to protect itself. Bloquear these signals allow the body to resume its natural fight against malignant cells.

Keytruda was developed as a monoclonal form of blocker of these checkpoints and has revolutionized the treatment of several types of cancer. Sua’s initial approval for melanoma opened the door for additional research that has led to its use in lung, kidney, head and neck cancers, among others. The medicine transformed the reality of tens of thousands of patients around the world, extending survival and improving quality of life.